INTRODUCTION
Upper tract urothelial cancer (UTUC) is an aggressive disease associated with significant morbidity and mortality (1) . At pre sentation, 30% of patients demonstrate invasive and/or locally advanced disease, 30%-40% have regional lymph node (LN) involvement, and 20% harbor metastatic disease (2) . Radical nephroureterectomy (RNU) with bladder cuff excision is con sidered the standard of care for most invasive UTUCs, but dis tant relapses are common following surgery for locally advanc ed, highgrade disease (3) . For patients with advanced disease, systemic recurrence and progression rates range from 45%-60% (2) . The 5year survival rates for patients classified with pT2 and pT3stage disease are 73% and 40%, respectively, and the medi an survival for patients with T4 stage disease is approximately 6 months. Given the inadequacy of radical surgery alone for pa tients with regionally advanced UTUC, a multimodal approach that includes perioperative chemotherapy regimens seems to be a promising approach (4) . Systemic chemotherapy in an ad juvant or neoadjuvant setting with local tumor control was ad opted in the 2013 National Comprehensive Cancer Network guideline (5) . Nevertheless, there is lack of consensus regarding the accurate identification of patients who may benefit from adjuvant chemotherapy and determine what factors are barri ers to systemic therapy eligibility. Renal insufficiency following RNU and nephrotoxic chemotherapy regimen seem to be chal lenges preventing the effective delivery of cisplatinbased che motherapy (68). Although general condition and systemic ill ness could be barriers for perioperative chemotherapy and also significant determinants of survival, the prognostic influences of comorbidity/performance indices on eligibility for adjuvant chemotherapy and survival in patients with UTUC remains un clear.
ORIGINAL ARTICLE
The American Society of Anesthesiologists Physical Status (ASAPS) classification system was first introduced in 1940 and has been updated and now includes a 6point scale, ranging from a healthy person (class 1) to one with a severe systemic disorder that is a constant threat to life (class 4). Class 5 was representing for moribund persons not expected to survive 24 hours, with or without surgery and the 6 class is now used for declared brain dead organ donors (9) . The ASAPS classification was originally designed as a standardized way for anesthesiologists to convey information about the patient's overall health status that allows outcomes to be stratified by a global assessment of their illness severity. In practice, however, the ASAPS score is frequently used to explicitly or implicitly estimate operative risk because it is the only instance for which overall preoperative condition is consistently preoperatively recorded for a large number of pa tients, and it correlates well with surgical mortality and morbid ity (9) . Moreover, the ASAPS system has a unique ability to quick ly and concisely summarize multiple patient characteristics (10) .
In this study, we tested our hypothesis that the ASAPS sys tem, as an assessment of systemic comorbidity/performance indices, may be associated with eligibility for adjuvant chemo therapy and potentially unfavorable survival outcomes in pa tients with UTUC who underwent RNU in 4 centers in Korea.
MATERIALS AND METHODS

Study population and data collection
We performed a retrospective analysis of 505 patients treated with RNU for UTUC at four academic centers in Korea. The da tabase listed patient characteristics including age, sex, body mass index (BMI), bladder cancer history, surgical approach (open vs. laparoscopic), tumor stage, grade, LN status (lympho vascular invasion), concomitant carcinoma in situ, tumor loca tion, use of adjuvant chemotherapy, prior endoscopic therapy, tumor multifocality, disease recurrence, and mortality from UTUC. The ASAPS classification was obtained from the anes thesia chart. All of the patients who had complete followup data available were considered for the analysis. A computerized databank was generated for the data transfer. After combining the data sets, reports were generated for each variable to identi fy inconsistencies and other data integrity problems. Prior to the final analysis, the database was frozen, and the final data set was produced for the current analysis (by HYS). Patients with an incomplete data set or those who received neoadjuvant che mo/radiotherapy were excluded. To avoid biasing the survival estimates, we also excluded patients with a history of radical cystectomy (RC) for treatment of previous or concomitant mus cleinvasive bladder tumor, distant metastases at diagnosis, and perioperative mortality within 1 month. The final study group comprised 416 patients.
Protocols for surgery and pathologic evaluation RNU was performed by a standard doubleaccess procedure (11) . The kidney, ureter, and a bladder cuff were excised en bloc. The hilar and regional LNs adjacent to the ipsilateral great ves sel were generally resected if they were palpable intraoperative ly or suspected based on preoperative imaging. All surgical spec imens were processed according to the standard pathologic pro cedures at each institution. The tumors were assessed accord ing to the 2002 American Joint Committee on TNM classifica tion (12) . Tumor grading was performed using the 1998 World Health Organization/International Society of Urologic Patholo gy consensus classification (13) . Tumor multifocality was defin ed as the synchronous presence of multiple tumors in the renal pelvis or ureter. Locally advanced UTUC was defined as ≥ pT3 and/or pN1 disease.
Follow-up protocol
After surgery, each patient was monitored according to the stan dard guidelines (14) . In general, patients were evaluated every 3-4 months for the first year following RNU, every 6 months from the second through fifth years, and annually thereafter. The followup included history taking, physical examination, routine blood and serum chemistry lab work, urinary cytology, chest radiography, cystoscopic evaluation of the urinary blad der, and radiographic evaluation of the contralateral upper uri nary tract. Elective bone scans, chest computed tomography, or magnetic resonance imaging was only performed when clini cally indicated. Adjuvant chemotherapy was administered at the surgeons' discretion based on tumor stage and overall health status.
Deaths were determined by reviewing medical records, and time to cancerspecific mortality (CSM) was calculated as the time from surgery to the date of cancerattributable mortality. Any patients who died without any proof of metastasis or recur rence were considered to have cancerindependent mortality (CIM).
Statistical analysis
Continuous variables are shown as medians and interquartile ranges (IQRs). Differences in variables with continuous distri butions across dichotomous categories were assessed using MannWhitney U tests. Fisher exact and χ 2 tests were used to evaluate associations between categorical variables. Cohorts were defined by ASAPS classification, and then pathologic re https://doi.org/10.3346/jkms.2017.32.2.335 sults and adjuvant chemotherapy eligibility were compared. KaplanMeier curves for overall survival (OS) and cancerspe cific survival (CSS) were generated and compared using log rank tests based on ASAPS classification. A subgroup analysis for locally advanced UTUC patients who may benefit from ad juvant chemotherapy was also performed. Univariate and mul tivariate survival analyses were performed using the Cox pro portional hazard regression model.
Differences were considered significant at P < 0.05, and all reported P values are 2sided. Analyses were performed using SPSS 20.0 software (IBM Corp., Armonk, NY, USA).
Ethics statement
The study was carried out in agreement with the applicable laws and regulations, good clinical practices, and ethical principles as described in the Declaration of Helsinki. The Institutional Review Board of Chungbuk National University approved this study protocol (Approval No.: GR201412009). Informed con sent was waived by the board.
RESULTS
Baseline characteristics
The clinical and pathologic characteristics of the patient cohort are shown in Table 1 .
Overall, 259 (62.3%) patients underwent laparoscopic neph rectomy, and the remaining 167 (38.0%) patients underwent open RNU. The stage distribution was 5.5% Ta, 1.9% Tis, 32.7% T1, 26.2% T2, 31.5% T3, and 2.2% T4. Overall, 75.2% had high grade UTUC. A total of 207 (49.7%) patients underwent concur rent regional LN dissection and 18 (4.3%) had metastasis to re gional LNs. Adjuvant chemotherapy was administered to 62 (14.9%) patients including 17 with localized but highrisk UTUC and 45 patients with locally advanced UTUC (defined as ≥ pT3 and/or pN1 disease).
ASA-PS score and adjuvant chemotherapy eligibility
Of the 416 patients included in this study, 118 (28.4%), 262 (63.0%), and 36 (8.7%) were assigned to the score 1, 2, and 3 groups, re spectively (Table 1) . Patient age was significantly increased with higher degrees of ASAPS classification (P < 0.001) ( Table 2 ). In addition, patients placed in higher ASAPS classes were less like ly to be eligible for adjuvant chemotherapy in the total cohort (P = 0.029) ( Table 2 ) and in the subgroup analysis limited to pa tients with locally advanced UTUC (P = 0.007) ( Table 3 ). There were no significant differences according to ASAPS classifica tion in terms of other clinicopathologic characteristics includ ing sex, history of previous or concomitant bladder cancer, patho logic stage or grade, LN status (lymphovascular invasion), tu mor necrosis, concomitant carcinoma in situ, tumor location, or multifocality (all P > 0.05) ( Table 2) .
ASA-PS score and survival in patients treated with RNU for UTUC
The median followup period of the study cohort was 30 months (IQR 15 to 52 months). During followup, 62 (14.9%) patients died of UTUC. KaplanMeier estimates showed that highrisk group (ASA 3) had a poorer OS and CSS compared to the low risk group (ASA 1-2) in the total and locally advanced UTUC cohorts ( Fig. 1A and 1B) . However, there was no significant sur vival impact of ASAPS score on OS or CSS in patients with lo calized UTUC (P = 0.475 and P = 0.399, respectively) (Fig. 1C) and high ASAPS score (HR, 1.919; 95% CI, 1.017-3.619; P = 0.044) were independent predictors of overall mortality (OM) ( (Table 5) .
DISCUSSION
In this study, we evaluated the prognostic value of the ASAPS scoring system on adjuvant chemotherapy eligibility and sur vival in a multicenter cohort of patients with UTUC treated with RNU. Our results show that the ASAPS classification as an as sessment of systemic comorbidity/performance indices was associated with adjuvant chemotherapy eligibility and poten tially unfavorable survival in this patient group. Comorbidity and performance status indices are useful clini cal tools to estimate the risk of comorbidities, which may guide decision making regarding operative procedures or multimodal therapy approaches. The most commonly used comorbidity in dices in the literature are the Charlson comorbidity index (CCI, ageadjusted Charlson comorbidity index [ACCI]), the ASAPS, the Adult Comorbidity Evaluation27 (ACE27), the Eastern Co operative Oncology Group (ECOG) performance status, and the Karnofsky Performance Status scale (KPS). The ASAPS score was first described in 1940 by Saklad (15) and is the oldest eval uation score that assesses perioperative risk. Although the ASA PS score was originally designed as a uniform system for anes thesiologists to convey information about the patient's overall health status, it has been shown to accurately predict perioper ative morbidity and mortality (9, 16, 17) . Furthermore, numer ous studies have suggested that the ASAPS score as an assess ment of systemic comorbidity/performance indices may pro vide prognostic information in many cancer surgeries includ ing urological malignancies such as prostate, bladder, and renal cell carcinoma. Anudeep and colleagues found that ASAPS score was associated with OS after minimally invasive partial nephrectomy for renal cell carcinoma (18) . The survival impact of ASA classification was also recognized in the radical prosta tectomy setting (1921). The predictive capacity of the ASAPS scoring with regard to OM and CSM in patients who underwent RC for bladder cancer remains unclear (2224). Several studies have also supported the prognostic role of comorbidity/perfor mance indices in patients with UTUC after RNU. For example, a large national multicenter collaborative study found that the ASA classification significantly correlated with CSS after RNU for UTUC. In this study, the 5year CSS differed significantly between ASA 1, 2, and 3 patients (83.8%, 76.9%, and 70.6%, re : 0 129  101  63  43  31  25  17  8  1  1  0  Group: 1 13  8  3  2  1  0  0  0  0  0  0   0  12  24  36  48  60  72  84  96 108 120   100  90  80  70  60  50  40  30  20 log-rank, P = 0.004
Overall survival (%)
Time (months after surgery)
Number at risk Group: 0 129  101  63  43  31  25  17  8  1  1  0  Group: 1 13  8  3  2  1  0  0  0  0  0  0   0  12  24  36  48  60  72  84  96  108 spectively), and there was a threefold higher risk of OM and CSM at 5 years for patients rated as ASA 3 compared with ASA 1 (25) . In a recent study by Aziz et al. (26) , 4 comorbidity indices (ASAPS, CCI, ACCI, and ECOGPS) were compared with re gard to recurrencefree survival (RFS), CSS, OS, and CIM. The ACCI and ECOGPS were associated with RFS and CSS, where as the ASAPS and ACCI scores were associated with CIM. Our results were similar to those described in previous stud ies in which a high ASAPS score was associated with poorer survival in patients with UTUC who underwent RNU. However, the present study is unique for several reasons. We analyzed the survival influence of ASAPS classification on the total cohort and also performed subgroup analyses for patients with local ized or locally advanced UTUC. We found that the survival in fluence of ASAPS classification was limited to locally advanced UTUC. There were no significant differences with regard to OS or CSS between the low and high ASAPS groups in patients with localized disease. Thus, radical surgery for localized UTUC might be reasonable and appropriate in patients with comor bidities. Of course, patients with a higher ASA have a higher need for preoperative optimization and critical postoperative care. Another strength of our study was that it considered a potential effect of adjuvant chemotherapy on survival outcomes in pa tients treated with RNU for UTUC. Such regimens could influ ence the longterm survival, especially CSS. Patients with a high er ASAPS class tended to less likely to be prescribed adjuvant chemotherapy in the locally advanced stage, and decreased eli gibility for adjuvant chemotherapy in the highrisk ASA catego ry may influence poorer survival in these patients. Although there is lack of evidence regarding a survival benefit for periop erative platinumbased chemotherapy in patients with highrisk UTUC, adjuvant chemotherapy in this clinical setting may have an effect on survival given the high risk of relapse in patients with locally advanced UTUC (27) .
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Our study had several inherent weaknesses. There are limita tions due to the retrospective and multicentric nature of the study; we excluded patients for whom we could not obtain complete information, which could have led to selection bias. Moreover, we could not adjust for surgeons' preferences, experience, or surgical techniques. There was also a lack of centralized patho logic review. However, all surgeons and pathologists operated at centers dedicated to the management of UTUC that followed the standard practice guidelines. Because comorbidities were measured using ASAPS scores obtained from the anesthesia chart, an effect of interobserver variability in ASA scoring be tween different anesthesiologists at the four study institutions cannot be ruled out. Finally, we did not have access to data on perioperative renal function, which could be confounding fac tor affecting chemotherapy eligibility. Nevertheless, our study provides evidence supporting the use of the ASAPS classifica tion to determine adjuvant chemotherapy eligibility and sur vival in patients with UTUC after RNU.
In conclusion, high ASAPS score was significantly associated with reduced eligibility for adjuvant chemotherapy and poorer survival of patients with UTUC after RNU. The subgroup analy sis revealed that the influence of ASAPS score on survival was limited to patients with locally advanced UTUC. The lower fea sibility of adjuvant chemotherapy in the highrisk ASA category may contribute to the lower survival rate in this group.
